HLS Therapeutics (TSX:HLS) Total Liabilities : C$125.18 Mil (As of Sep. 2024)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Total Liabilities?

HLS Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 was C$125.18 Mil.

HLS Therapeutics's quarterly Total Liabilities increased from Mar. 2024 (C$147.12 Mil) to Jun. 2024 (C$148.86 Mil) but then declined from Jun. 2024 (C$148.86 Mil) to Sep. 2024 (C$125.18 Mil).

HLS Therapeutics's annual Total Liabilities increased from Dec. 2021 (C$147.42 Mil) to Dec. 2022 (C$158.04 Mil) but then declined from Dec. 2022 (C$158.04 Mil) to Dec. 2023 (C$149.41 Mil).

HLS Therapeutics Total Liabilities Historical Data

The historical data trend for HLS Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Total Liabilities Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

186.30

172.48

147.42

158.04

149.41

HLS Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															153.48	149.41	147.12	148.86	125.18

HLS Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

HLS Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	35.805	+	(110.635	+	2.372
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.593	+	0)
	=	149.41

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	280.475	-	131.07
	=	149.41

HLS Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32.634	+	(86.434	+	0.99600000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.116	+	0)
	=	125.18

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	232.639	-	107.459
	=	125.18

HLS Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

Executives

Norma Beauchamp	Director
Craig Millian	Director, Senior Officer
Brian Thomas Walsh	Senior Officer
Polar Asset Management Partners Inc.	10% Security Holder
John Gordon Hanna	Director, Senior Officer
Athyrium Opportunities Ii Co-invest 1 Lp	10% Security Holder
Jr. John Lee Welborn	Director
Tim Hendrickson	Senior Officer
William M. Wells	Director, Senior Officer
Gilbert Godin	Director, Senior Officer
Gregory David Gubitz	Director
Orbimed Advisors Llc	10% Security Holder
Jason Gross	Senior Officer
Ryan Christopher Lennox	Senior Officer

HLS Therapeutics Headlines

No Headlines